Jouanny_2005_Psychol.Neuropsychiatr.Vieil_3 Suppl 1_S51

Reference

Title : [Pharmacological treatment in severe dementia] - Jouanny_2005_Psychol.Neuropsychiatr.Vieil_3 Suppl 1_S51
Author(s) : Jouanny P , Belliard S , Bentue-Ferrer D , Michel O , Allain H
Ref : Psychol Neuropsychiatr Vieil , 3 Suppl 1 :S51 , 2005
Abstract :

Medical treatment of severe dementia is now available. Decrease of psychobehavioral disturbances, autonomy loss or care-giver burden appear as the main objective rather than reduction of cognitive deficits. Acetylcholinesterase inhibitors (AChE-I) should be maintained in patients with severe dementia when initiated in mild or moderate dementia. Memantine is the specific treatment for patients with severe dementia, even if they received AChE-I. To treat the psychobehavioral disturbancies, serotoninergic agents and thymoregulators are the first line drugs. Medical treatment should only be co-prescribed with a global care of all co-morbidities, autonomy loss and patient's and care-giver's burden, and associated with psychological and organisational support.

PubMedSearch : Jouanny_2005_Psychol.Neuropsychiatr.Vieil_3 Suppl 1_S51
PubMedID: 15899605

Related information

Citations formats

Jouanny P, Belliard S, Bentue-Ferrer D, Michel O, Allain H (2005)
[Pharmacological treatment in severe dementia]
Psychol Neuropsychiatr Vieil 3 Suppl 1 :S51

Jouanny P, Belliard S, Bentue-Ferrer D, Michel O, Allain H (2005)
Psychol Neuropsychiatr Vieil 3 Suppl 1 :S51